Doripenem (doribax), a new carbapenem antibacterial agent.
Year: 2008
Type: article
Abstract: Carbapenems represent a class of beta-lactam antibacterial agents with a broad spectrum of activity against gram-positive, gram-negative, and anaerobic bacteria. This class is bactericidal in nature, but it does not cover species of Enterococcus faecium, methicillin-resistant Staphylococcus aureus (MRSA), or Stenotrophomonas maltophilia.
Collectively, the carbapenems have been used to treat a variety of infections. As with all antibiotics, resistance within the carbapenem class is a major concern. Although carbapenems remain the drugs of choice for extended-spectrum, beta-lactamase–producing organisms, resistance may emerge via other beta-lactamases, such as metallo–beta-lactamases, alteration of porin channels, or up-regulation of efflux pumps. Therefore, carbapenems should be used judiciously, and the appropriate use of these agents must be considered carefully.1,2
The Food and Drug Administration (FDA) has approved four carbapenems:
imipenem (a primary component of Primaxin IM, Merck)
meropenem (Merrem IV, Astra-Zeneca)
ertapenem (Invanz, Merck)
doripenem (Doribax, Ortho-McNeil)
Imipenem and meropenem are veteran agents of the carbapenem class and are used primarily to treat moderate-to-severe nosocomial and polymicrobial infections, including intra-abdominal infections, nosocomial pneumonia, septicemia, and febrile neutropenia. Imipenem possesses slightly more potent in vitro activity against gram-positive pathogens, whereas meropenem possesses slightly more potent in vitro activity against gram-negative pathogens, including Pseudomonas aeruginosa.
Imipenem has a greater tendency to precipitate seizures; thus, caution must be taken, particularly among patients with impaired renal function. This carbapenem is also extremely susceptible to degradation via the enzyme dehydropeptidase-1 (DHP-1). In order to resolve this problem and ensure stability, the DHP-1 inhibitor cilastatin is used concomitantly with imipenem. The combination of imipenem/cilastatin is commonly known by its brand name, Primaxin IM.1,3,4
Compared with other carbapenems, ertapenem displays a decrease in activity against nosocomial infections associated with Enterococcus spp., Acinetobacter spp., and P. aeruginosa. Comparative trials have confirmed that ertapenem has comparable efficacy with piperacillin/tazobactam (Zosyn, Wyeth) and ceftriaxone (Rocephin, Roche) for the treatment of complicated intra-abdominal infections, acute pelvic infections, complicated surgical-site infections, community-acquired pneumonia, complicated urinary tract infections (UTIs), and diabetic foot infections.
Ertapenem is used and clinically suitable primarily for the empirical coverage of severe infections when Acinetobacter spp. and P. aeruginosa are the unlikely causes of suspected infections. It is also preferred for outpatient use as a result of its favorable pharmacokinetic profile. However, ertapenem must be prescribed with caution because of its potential overuse, which may lead to an increase in resistance of this class of antimicrobials.1,4
In October 2007, the FDA approved the most recent addition to the carbapenem class, doripenem (Doribax). Doripenem seems to most closely resemble the profile of meropenem, except for its increased potency of in vitro activity against P. aeruginosa. It is indicated for patients with complicated intra-abdominal infections and UTIs, including pyelonephritis, when the infection is caused by susceptible bacteria.5–7
Source: PubMed
Language: English
Subfield: Microbiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2131353439
